ArticlePloS one2024
Developing a short form of the Awe Experience Scale (AWE-SF) in psychedelic samples.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- From awe to anxiety: investigating art-induced self-transcendence using virtual reality.Frontiers in psychology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to develop and validate a short-form version of the AWE-S (AWE-SF) within psychedelic samples, to reduce participant burden while maintaining psychometric integrity. Across five studies, we first replicated the original six-factor structure of the AWE-S through exploratory and confirmatory factor analyses (Study 1), leading to the creation of the 12-item AWE-SF (Study 2-3). We then established the AWE-SF's initial and predictive validity by correlating it with relevant emotional, psychedelic, and well-being outcomes (Study 4-6). The AWE-SF demonstrated strong positive associations with positive emotions and was also linked to openness to experience. Moreover, the AWE-SF effectively predicted both mystical-type and challenging psychedelic experiences, as well as long-term well-being outcomes such as life satisfaction and psychological richness. In particular, the facets of connection and vastness were associated with positive emotional states and mystical-type experience, while accommodation and self-loss were associated with negative emotional states and challenging psychedelic experience. These findings suggest that the AWE-SF is a robust, reliable, and accessible tool for measuring awe experience.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.